ElliotShinMD

Family Medicine • Las Vegas, NV

Urgent Care

Principal Investigator

Join to view full profile

Dr. Shin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shin's full profile

Already have an account?

Office
400 Shadow Lane
Suite 205
Las Vegas, NV 89106
Phone+1 702-631-5000

Fax+1 702-631-5002
Is this information wrong?

Summary

I am a board certified family physician and principal investigator conducting various multi-specialty clinical trials. I also have a non-profit clinic that helps the uninsured low-income families and homeless individuals.

Education & Training

In His Image at St John Medical CenterResidency, Family Medicine, 2000 - 2003
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2000

Certifications & Licensure

FL State Medical License 2022 - 2025
NV State Medical License 2006 - 2025
TX State Medical License 2003 - 2007
OK State Medical License 2001 - 2003
American Board of Family Medicine Family Medicine

Clinical Trials

Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm Start of enrollment: 2020 Dec 15
Completed
Phase 3
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) Start of enrollment: 2019 Dec 30
Active, not recruiting
Phase 3
Roles: Contact
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive Start of enrollment: 2022 Feb 17
Terminated
Phase 3
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

56 citations
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, ...
William O'Riordan, Carrie Cardenas, Elliot Shin, Alissa Sirbu, Lynne Garrity-Ryan, Anita Das, Paul B. Eckburg, Amy Manley, Judith N. Steenbergen, Evan Tzanis, Paul C. ...> ;The Lancet. Infectious Diseases. 2019 Oct 1

Journal Articles

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, ...
W O'Riordan, C Cardenas, E Shin, Lancet, 10/1/2019

Authored Content

Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trialOctober 2019

Press Mentions

Doctor Treats Homeless for Free; Asks Patients to Pay It ForwardMarch 10th, 2020

Other Languages

Korean